Monitoring Agency Report for quarter ended 30th June 2026

FISCHER MEDICAL VENTURES LIMITED (Formerly known as Fischer Chemic Limited) Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: enquiry@fischermv.com | Website: www.fischermv.com | Contact 9080966548 August 13, 2026 BSE Limited National Stock Exchange of India Ltd. Corporate Relationship Department Exchange Plaza, 5tll floor 25th Floor, P J Towers Plot No. C/ 1, G Block, Dalal Street, Fort, Bandra-Kurla Complex Bandra (E), Mumbai – 400 001 Mumbai - 400 051 BSE Scrip Code: 524743 NSE Symbol: FISCHER Dear Sir / Madam, Reg : Regulation 32(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 162A (4) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 Dear Sir/Madam, Pursuant to Regulation 162A (4) of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 read with Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith Monitoring Agency Report issued by Infomerics Valuation and Rating Limited, Monitoring Agency, for the quarter ended June 30, 2026 in respect of utilisation of funds raised pursuant to the issue of shares on preferential basis. The report is also placed on the Company’s website at www.fischermv.com Thanking You, Yours Truly, For FISCHER MEDICAL VENTURES LIMITED BALAJI GANDLA COMPANY SECRETARY & COMPLIANCE OFFICER Corporate Office: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006 Monitoring Agency Report for Fischer Medical Ventures Limited for the quarter ended June 30, 2026 Monitoring Agency Report August 13th, 2026 Fischer Medical Ventures Limited No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Vishakapatnam, Nadupuru, 530044 Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Preferential issue of Fischer Medical Ventures Limited (“The Company”) We write in our capacity of Monitoring Agency for the Preferential issue of the Equity shares and fully convertible share warrants for the amount aggregating to Rs. 358.46 crore of the Company and refer to our duties cast under 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations). In this connection, we are enclosing the Monitoring Agency Report for the quarter ended June 30, 2026, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated 19th February 2025. Request you to kindly take the same on records. Thanking you, For and on behalf of Infomerics Valuation and Rating Limited Rekha Chokkalingam (Associate Director - Ratings) rekha.chokkalingam@infomerics.com Report of the Monitoring Agency Name of the Issuer: Fischer Medical Ventures Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Infomerics Valuation and Rating Limited (a) Deviation from the objects: Nil (b) Range of Deviation: Nil Indicate range of percentage deviation from the amount of issue proceeds earmarked for objects. For example, up to 10%, 10 – 25%, 25-50%, 50-75%, 75-100%, not ascertainable etc. * Range of Deviation may be computed by taking weighted average of financial deviation of each object in the ratio of issue proceeds allocated for it. Non-financial deviation may be indicated separately by way of notes. Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer. We further declare that this report provides true and fair view of the utilization of issue proceeds. Signature: Name of the Authorized Person/Signing Authority: Rekha Chokkalingam Designation of Authorized person/Signing Authority: Associate Director - Ratings Seal of the Monitoring Agency: Date: August 13th, 2026 1) Issuer Details: Name of the issuer: Fischer Medical Ventures Limited Names of the promoters of the issuer: Time Medical International Ventures Pte Industry/sector to which it belongs: Engaged in the business of manufacturing and supplying magnetic resonance imaging machines and preventive healthcare devices and has an established client base in the healthcare industry. 2) Issue Details: Issue Period: 18 Months from the date of allotment (18th February 2025) Type of issue (public/rights): Preferential Issue Type of specified securities: Equity shares and fully convertible share warrants Grading: Not Applicable Issue size (Rs in Crores): Rs. 358.46 crores (Note No. 1& 2) Note 1 The company had offered 1,05,22,000 Equity Shares Rs. 234.00 per share (including share premium of Rs. 224.00 per share) on preferential basis aggregating to Rs. 246.21 crore. The issue was subscribed, and the company has allotted 1,03,01,547 Equity Shares to the applicants during the quarter ended March 2025. Note 2 The offer comprises of 50,17,000 warrants of the company convertible into equal number of equity shares at a price of Rs.234.00 per warrant as determined on the relevant date (for the purpose of calculating the price of equity warrants convertible into equal number of equity shares to be issued) in accordance with the provisions of Chapter V of the SEBI ICDR Regulations aggregating to Rs. 117.40 Crore for cash consideration by way of preferential allotment to Specified investors/Identified investors which also includes promoters and members of promoter group of the company. Particulars Remarks Amount (in Rs. crore) Approved by EGM Total shares to be issued and subscribed as part of Preferential Issue (A) 1,05,22,000 246.21 Total Warrants to be issued (B) 50,17,000# 117.40 Total - 363.61 Details of expenses to be incurred - - Net Proceeds to be received - 363.61* Current Status 1,03,01,547 (10,30,15,470 post sub- Total shares issued and subscribed as part of Preferential Issue (A) 241.05 division) 6,00,000 (60,00,000 post sub- Total Warrants converted in to shares during the period (Fully paid up) (C) 14.04 division) Warrants – 25% Share Application money (still outstanding to be exercised within 44,17,000# (4,41,70,000 post sub- 25.84 18 months from the date of allotment (Deposit amount received) (D) division) Total subscriptions towards Preferential issue (A + C + D) 280.93 Details of expenses incurred related to issue - - Net Proceeds receipt # Each Warrant held by the Proposed Allottee shall entitle each of them to apply for and ob [Showing first 8,000 characters — download PDF for full document]